Eganelisib, a First-in-Class PI3K-γ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial

By sjmartinez • April 1, 2023

Hong DS, Postow M, Chmielowski B, Sullivan R, Patnaik A, Cohen EEW, Shapiro G, Steuer C, Gutierrez M, Yeckes-Rodin H, Ilaria R, O'Connell B, Peng J, Peng G, Zizlsperger N, Tolcher A, Wolchok JD. Eganelisib, a First-in-Class PI3K-γ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial. Clin Cancer Res. 2023 Mar 31:CCR-22-3313. doi: 10.1158/1078-0432.CCR-22-3313. Epub ahead of print. PMID: 37000164.

Tags: Hematology/Oncology, Publications

Impact of timing of pregnancy and genetic risk on local therapy choices for young women with breast cancer

Lipsyc-Sharf M, Huang M, Huang SY, Suresh YK, Doll A, Baker JL, Kapoor NS. Impact of timing of pregnancy and genetic risk on local therapy[...]

A Multi-Enzyme Nanocascade to Target Disease-Relevant Metabolites

Cao Z, Ren J, Yang A, Wang Z, Love M, Chen W, Yuan X, Guo X, Chen I, Lu Y, Wen J. A Multi-Enzyme Nanocascade[...]

Transformation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma to Histiocytic/Dendritic Cell Sarcoma

Cai J, Fernandez-Hazoury D, Yoshikawa G, Minja A, Huang H, Hwang A, Qing X. Transformation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma to Histiocytic/Dendritic Cell Sarcoma.[...]